Developer docs
API playgroundTry for free, no card

Search company profiles

Kyverna Therapeutics

Full company profile

uuid00004ng

Namestring
Kyverna Therapeutics
Legal namestring
Kyverna Therapeutics, Inc.
Websiteurl
kyvernatx.com
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing engineered T-cell therapies for B-cell-driven autoimmune diseases. The company's lead candidate, mivocabtagene autoleucel (miv-cel, also designated KYV-101), is an autologous CAR-T therapy built on a fully human anti-CD19 chimeric antigen receptor construct designed to reduce immunogenicity compared with murine-based predecessors. The pipeline also extends to allogeneic and next-generation formats (KYV-201 and KYV-102) developed on the company's Ingenui-T manufacturing platform. Kyverna initiated the first rolling Biologics License Application for a CAR-T therapy in an autoimmune indication, targeting stiff person syndrome (SPS), and is running parallel KYSA Phase 1/2 trials in generalized myasthenia gravis, lupus nephritis, multiple sclerosis, systemic sclerosis, and rheumatoid arthritis.

The company is headquartered in Emeryville, California, completed its initial public offering on Nasdaq (ticker KYTX) in 2024, and subsequently raised additional capital through a 2025 follow-on equity offering and a $150 million non-dilutive term loan facility with Oxford Finance. The senior leadership team has been deliberately built with executives drawn from Kite Pharma, the first company to commercialize an autologous CAR-T therapy, signaling preparation for a commercial launch in the United States. A manufacturing automation partnership with Multiply Labs reflects investment in reducing cost-of-goods and scaling treatment-center throughput, both critical to extending CAR-T beyond oncology.

Kyverna's intended business model is a specialty biopharma model in which an autologous cell therapy is delivered through authorized treatment centers under a buy-and-bill reimbursement framework typical of high-cost cell and gene therapies. The company is pre-revenue and pre-commercial, with no approved product; revenue generation is contingent on regulatory approval, manufacturing scale-up, and successful launch execution across multiple rare autoimmune indications.

Short descriptiontext

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing autologous and allogeneic anti-CD19 CAR T-cell therapies for B-cell-driven autoimmune diseases, with lead candidate miv-cel (KYV-101) advancing through registrational trials in stiff person syndrome, myasthenia gravis, lupus nephritis, and multiple sclerosis.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CAR T-cell therapy, cell therapy autoimmune, anti-CD19 immunotherapy, clinical-stage biopharmaceutical, B-cell depletion therapy
Industry4 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical and Diagnostic Laboratories62151
  • Medical and Diagnostic Laboratories6215
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • In Vitro & In Vivo Diagnostic Substances2835
  • Pharmaceutical Preparations2834
Product category
Cell Therapy Biopharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Future cell therapy product sales (miv-cel / KYV-101)
TypeHardware Sales
Description

Pre-revenue clinical-stage biopharmaceutical company; primary future revenue stream will come from one-time sales of autologous CAR-T cell therapy doses administered at authorized treatment centers. Buy-and-bill reimbursement model is being prepared for in the CAR T Channel Strategy & Operations build-out, with specialty pharmacy and 3PL distribution infrastructure planned. Initial commercial launch targeted in stiff person syndrome with expansion into generalized myasthenia gravis, lupus nephritis, multiple sclerosis, rheumatoid arthritis, and systemic sclerosis.

kyvernatx.com
2Potential licensing / collaboration revenue (KYV-102 / allogeneic platform)
TypeLicensing Royalties
Description

Adjacent revenue optionality from allogeneic platform programs (KYV-201, KYV-102) and external collaborations such as the Multiply Labs pilot to automate CAR-T manufacturing, which could enable licensing or partnership economics as the platform matures.

thepharmaletter.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Pricing not publicly disclosed — investigational therapy pre-approval
ModelOtherBilling cadencePay-as-you-go
Notes

No public price has been set. Reimbursement strategy is being built around buy-and-bill and specialty distribution models consistent with autologous CAR-T cell therapies.

kyvernatx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1mivocabtagene autoleucel
Description

Lead CAR T-cell therapy candidate, also referred to as miv-cel or KYV-101, an autologous anti-CD19 CAR T-cell product targeting B cells in autoimmune diseases.

kyvernatx.com
+1 more record
Core offering1 text field

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing CAR T-cell therapies (chimeric antigen receptor T-cell therapies) for serious B-cell-driven autoimmune diseases. Its lead candidate, mivocabtagene autoleucel (miv-cel / KYV-101), is a fully human anti-CD19 CAR T-cell therapy designed to deliver deep B-cell depletion and durable immune reset after a single infusion. The pipeline targets stiff person syndrome, generalized myasthenia gravis, multiple sclerosis, lupus nephritis, systemic sclerosis, and treatment-refractory rheumatoid arthritis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 46% median improvement in walking ability (T25FW) at week 16 in KYSA-8 SPS registrational trial
+4 more records
Product overview1 text field

Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing a single platform-plus-pipeline architecture centered on its proprietary anti-CD19 CAR T-cell therapy platform. The core product candidate mivocabtagene autoleucel (miv-cel / KYV-101) — a fully human autologous anti-CD19 CAR T-cell therapy — is the lead asset and is being evaluated across neurology and rheumatology autoimmune indications (stiff person syndrome, myasthenia gravis, multiple sclerosis, systemic sclerosis, and lupus nephritis). Building on the KYV-101 program, the pipeline expands into next-generation candidates including the allogeneic anti-CD19 CAR T-cell therapy KYV-201 and the manufacturing-automated candidate KYV-102 (developed in collaboration with Multiply Labs), supported internally by the rapid whole-blood autologous manufacturing process Ingenui-T. Together these constitute Kyverna's portfolio of B-cell-targeted CAR T-cell therapies intended to deliver durable, drug-free remission after a single infusion in B-cell-driven autoimmune diseases.

Product and service3 records
1Mivocabtagene autoleucel (miv-cel, KYV-101)
CategoryLead cell therapy product candidate (autologous CAR T)
Description

Fully human anti-CD19 CAR T-cell therapy candidate (autologous) and Kyverna's lead asset, advancing through clinical development in rheumatology and neurology autoimmune indications including stiff person syndrome, myasthenia gravis, multiple sclerosis, systemic sclerosis, and lupus nephritis. Designed to achieve deep B-cell depletion, immune reset, and durable drug-free remission after a single administration.

2KYV-201
CategoryAllogeneic CAR T pipeline product candidate
Description

Investigational allogeneic (off-the-shelf) anti-CD19 CAR T-cell therapy for the treatment of autoimmune disease, intended to complement Kyverna's autologous KYV-101 by eliminating the need for patient-specific manufacturing.

3KYV-102
CategoryPipeline CAR T product candidate (automated manufacturing)
Description

CAR-T cell therapy candidate whose manufacturing is being automated in a pilot collaboration with Multiply Labs (initiated mid-2025), using cloud-controlled robotic systems to reduce manufacturing cost and increase throughput.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierModerateTypeTechnology or IntegrationAnnounced on2025-06-01
Description

Pilot collaboration initiated mid-2025 to automate manufacturing of Kyverna's CAR-T candidate KYV-102 using Multiply Labs' cloud-controlled robotic systems. Multiply Labs has demonstrated 74% reduction in manufacturing costs and up to 100x more patient doses per square foot of cleanroom versus manual processes. Kyverna is among Multiply Labs' strategic partners alongside AstraZeneca, NVIDIA, Thermo Fisher Scientific, Legend Biotech, WuXi STA, Charles River Laboratories, and Cytiva.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing CD19 CAR-T cell therapies (e.g., CABA-201) for autoimmune diseases including lupus, myositis, and pemphigus. Direct competitor to Kyverna in the autoimmune CAR-T space with overlapping anti-CD19 mechanism and B-cell depletion thesis.

TypeDirect peer
Description

Clinical-stage company developing mRNA-engineered cell therapies for autoimmune diseases, including Cartesian's lead program in myasthenia gravis. Directly competes with Kyverna's miv-cel in gMG and pursues a similar cell-therapy-for-autoimmune repositioning strategy.

3Bristol Myers Squibb
TypeBroad incumbent
Description

Large pharmaceutical company with approved CD19 CAR-T therapy Breyanzi (lisocabtagene maraleucel) in oncology and active autoimmune pipeline. Represents both a competitor and potential acquirer/partner for Kyverna given overlapping CD19 CAR-T modality and autoimmune ambitions.

TypeBroad incumbent
Description

Owns Kite Pharma, the leading commercial CAR-T franchise (Yescarta, Tecartus) and a Series B investor in Kyverna. Kite is the most established CAR-T commercial organization and a direct comparator for Kyverna's commercial buildout, while also being a potential strategic acquirer.

TypeBroad incumbent
Description

Pioneer of CAR-T therapy with Kymriah (tisagenlecleucel) and a major biopharmaceutical incumbent with deep cell therapy manufacturing infrastructure. Multiple Kyverna executives (e.g., CTO Mayo Pujols) came from Novartis cell and gene therapy operations.

TypeEmerging player
Description

Clinical-stage biotech developing allogeneic (off-the-shelf) CAR-T therapies with a platform that mirrors Kyverna's allogeneic KYV-201 ambitions. Comparable on modality and pipeline breadth, with deeper oncology focus but adjacent autoimmune relevance.

TypeEmerging player
Description

Clinical-stage allogeneic T-cell therapy company with a comparable leadership connection (Kyverna CBO Dan Maziasz was formerly Atara's CBO). Atara's tabelecleucel and allogeneic platform overlap with Kyverna's KYV-201 in modality and target indications.

TypeEmerging player
Description

Clinical-stage allogeneic CAR-T developer using CRISPR-edited cell therapies (CB-010, CB-012). Comparable to Kyverna on next-generation engineered cell therapy platform though focused primarily on oncology, with potential autoimmune expansion.

TypeBroad incumbent
Description

Co-developer of Carvykti (BCMA CAR-T) with Legend Biotech, giving J&J deep CAR-T commercial and manufacturing capability relevant to Kyverna's launch model. Broad biopharma incumbent exploring autoimmune applications of cell therapy.

TypeOthers
Description

Gene-editing cell therapy company with Casgevy (exa-cel) approval and an active autoimmune pipeline (CTX112, CTX131). Thematically aligned as a next-generation cell therapy platform, with overlapping modality but differentiated gene-editing versus CAR-T approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kyverna Therapeutics

Cell Therapy Biopharmaceuticalskyvernatx.com

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing autologous and allogeneic anti-CD19 CAR T-cell therapies for B-cell-driven autoimmune diseases, with lead candidate miv-cel (KYV-101) advancing through registrational trials in stiff person syndrome, myasthenia gravis, lupus nephritis, and multiple sclerosis.

What Kyverna Therapeutics does

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing engineered T-cell therapies for B-cell-driven autoimmune diseases. The company's lead candidate, mivocabtagene autoleucel (miv-cel, also designated KYV-101), is an autologous CAR-T therapy built on a fully human anti-CD19 chimeric antigen receptor construct designed to reduce immunogenicity compared with murine-based predecessors. The pipeline also extends to allogeneic and next-generation formats (KYV-201 and KYV-102) developed on the company's Ingenui-T manufacturing platform. Kyverna initiated the first rolling Biologics License Application for a CAR-T therapy in an autoimmune indication, targeting stiff person syndrome (SPS), and is running parallel KYSA Phase 1/2 trials in generalized myasthenia gravis, lupus nephritis, multiple sclerosis, systemic sclerosis, and rheumatoid arthritis.

The company is headquartered in Emeryville, California, completed its initial public offering on Nasdaq (ticker KYTX) in 2024, and subsequently raised additional capital through a 2025 follow-on equity offering and a $150 million non-dilutive term loan facility with Oxford Finance. The senior leadership team has been deliberately built with executives drawn from Kite Pharma, the first company to commercialize an autologous CAR-T therapy, signaling preparation for a commercial launch in the United States. A manufacturing automation partnership with Multiply Labs reflects investment in reducing cost-of-goods and scaling treatment-center throughput, both critical to extending CAR-T beyond oncology.

Kyverna's intended business model is a specialty biopharma model in which an autologous cell therapy is delivered through authorized treatment centers under a buy-and-bill reimbursement framework typical of high-cost cell and gene therapies. The company is pre-revenue and pre-commercial, with no approved product; revenue generation is contingent on regulatory approval, manufacturing scale-up, and successful launch execution across multiple rare autoimmune indications.

Kyverna Therapeutics firmographics

Firmographics
Name
Kyverna Therapeutics
Legal name
Kyverna Therapeutics, Inc.
Website
https://kyvernatx.com
Company type
Public
Founded year
2020
Operating status
Ipo
Headcount range
101–250 employees
Short description
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing autologous and allogeneic anti-CD19 CAR T-cell therapies for B-cell-driven autoimmune diseases, with lead candidate miv-cel (KYV-101) advancing through registrational trials in stiff person syndrome, myasthenia gravis, lupus nephritis, and multiple sclerosis.
Ownership category
akta.pro rank

Kyverna Therapeutics industry classification

Industry
Product category
Cell Therapy Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
SIC
Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • CAR T-cell therapy
  • Cell therapy autoimmune
  • Anti-CD19 immunotherapy
  • Clinical-stage biopharmaceutical
  • B-cell depletion therapy

Where Kyverna Therapeutics is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Kyverna Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Future cell therapy product sales (miv-cel / KYV-101): Pre-revenue clinical-stage biopharmaceutical company; primary future revenue stream will come from one-time sales of autologous CAR-T cell therapy doses administered at authorized treatment centers. Buy-and-bill reimbursement model is being prepared for in the CAR T Channel Strategy & Operations build-out, with specialty pharmacy and 3PL distribution infrastructure planned. Initial commercial launch targeted in stiff person syndrome with expansion into generalized myasthenia gravis, lupus nephritis, multiple sclerosis, rheumatoid arthritis, and systemic sclerosis.
  2. Potential licensing / collaboration revenue (KYV-102 / allogeneic platform): Adjacent revenue optionality from allogeneic platform programs (KYV-201, KYV-102) and external collaborations such as the Multiply Labs pilot to automate CAR-T manufacturing, which could enable licensing or partnership economics as the platform matures.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPricing not publicly disclosed — investigational therapy pre-approval

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Kyverna Therapeutics product offering

Product offering

Core offering

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing CAR T-cell therapies (chimeric antigen receptor T-cell therapies) for serious B-cell-driven autoimmune diseases. Its lead candidate, mivocabtagene autoleucel (miv-cel / KYV-101), is a fully human anti-CD19 CAR T-cell therapy designed to deliver deep B-cell depletion and durable immune reset after a single infusion. The pipeline targets stiff person syndrome, generalized myasthenia gravis, multiple sclerosis, lupus nephritis, systemic sclerosis, and treatment-refractory rheumatoid arthritis.

Product overview

Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing a single platform-plus-pipeline architecture centered on its proprietary anti-CD19 CAR T-cell therapy platform. The core product candidate mivocabtagene autoleucel (miv-cel / KYV-101) — a fully human autologous anti-CD19 CAR T-cell therapy — is the lead asset and is being evaluated across neurology and rheumatology autoimmune indications (stiff person syndrome, myasthenia gravis, multiple sclerosis, systemic sclerosis, and lupus nephritis). Building on the KYV-101 program, the pipeline expands into next-generation candidates including the allogeneic anti-CD19 CAR T-cell therapy KYV-201 and the manufacturing-automated candidate KYV-102 (developed in collaboration with Multiply Labs), supported internally by the rapid whole-blood autologous manufacturing process Ingenui-T. Together these constitute Kyverna's portfolio of B-cell-targeted CAR T-cell therapies intended to deliver durable, drug-free remission after a single infusion in B-cell-driven autoimmune diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • mivocabtagene autoleucel: Lead CAR T-cell therapy candidate, also referred to as miv-cel or KYV-101, an autologous anti-CD19 CAR T-cell product targeting B cells in autoimmune diseases.
  • KYV-201

Products and services

  • Mivocabtagene autoleucel (miv-cel, KYV-101) Fully human anti-CD19 CAR T-cell therapy candidate (autologous) and Kyverna's lead asset, advancing through clinical development in rheumatology and neurology autoimmune indications including stiff person syndrome, myasthenia gravis, multiple sclerosis, systemic sclerosis, and lupus nephritis. Designed to achieve deep B-cell depletion, immune reset, and durable drug-free remission after a single administration.
  • KYV-201 Investigational allogeneic (off-the-shelf) anti-CD19 CAR T-cell therapy for the treatment of autoimmune disease, intended to complement Kyverna's autologous KYV-101 by eliminating the need for patient-specific manufacturing.
  • KYV-102 CAR-T cell therapy candidate whose manufacturing is being automated in a pilot collaboration with Multiply Labs (initiated mid-2025), using cloud-controlled robotic systems to reduce manufacturing cost and increase throughput.

Quantifiable outcome

  • 46% median improvement in walking ability (T25FW) at week 16 in KYSA-8 SPS registrational trial
  • +4 more outcomes

Companies that use Kyverna Therapeutics

Customer profile

Segments6 records

Ideal customer profiles3 records

Kyverna Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Kyverna Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Multiply LabsmoderateTechnology or Integration · 1 June 2025Pilot collaboration initiated mid-2025 to automate manufacturing of Kyverna's CAR-T candidate KYV-102 using Multiply Labs' cloud-controlled robotic systems. Multiply Labs has demonstrated 74% reduction in manufacturing costs and up to 100x more patient doses per square foot of cleanroom versus manual processes. Kyverna is among Multiply Labs' strategic partners alongside AstraZeneca, NVIDIA, Thermo Fisher Scientific, Legend Biotech, WuXi STA, Charles River Laboratories, and Cytiva.

Scale indicators15 records

Recent moves7 records

Expansion highlights7 records

Kyverna Therapeutics competitors and assessment

Company assessment

Direct peers

  • Cabaletta Bio: Clinical-stage biotech developing CD19 CAR-T cell therapies (e.g., CABA-201) for autoimmune diseases including lupus, myositis, and pemphigus. Direct competitor to Kyverna in the autoimmune CAR-T space with overlapping anti-CD19 mechanism and B-cell depletion thesis.
  • Cartesian Therapeutics: Clinical-stage company developing mRNA-engineered cell therapies for autoimmune diseases, including Cartesian's lead program in myasthenia gravis. Directly competes with Kyverna's miv-cel in gMG and pursues a similar cell-therapy-for-autoimmune repositioning strategy.

Broad incumbents

  • Bristol Myers Squibb: Large pharmaceutical company with approved CD19 CAR-T therapy Breyanzi (lisocabtagene maraleucel) in oncology and active autoimmune pipeline. Represents both a competitor and potential acquirer/partner for Kyverna given overlapping CD19 CAR-T modality and autoimmune ambitions.
  • Gilead Sciences (Kite Pharma): Owns Kite Pharma, the leading commercial CAR-T franchise (Yescarta, Tecartus) and a Series B investor in Kyverna. Kite is the most established CAR-T commercial organization and a direct comparator for Kyverna's commercial buildout, while also being a potential strategic acquirer.
  • Novartis: Pioneer of CAR-T therapy with Kymriah (tisagenlecleucel) and a major biopharmaceutical incumbent with deep cell therapy manufacturing infrastructure. Multiple Kyverna executives (e.g., CTO Mayo Pujols) came from Novartis cell and gene therapy operations.
  • Johnson & Johnson: Co-developer of Carvykti (BCMA CAR-T) with Legend Biotech, giving J&J deep CAR-T commercial and manufacturing capability relevant to Kyverna's launch model. Broad biopharma incumbent exploring autoimmune applications of cell therapy.

Emerging players

  • Allogene Therapeutics: Clinical-stage biotech developing allogeneic (off-the-shelf) CAR-T therapies with a platform that mirrors Kyverna's allogeneic KYV-201 ambitions. Comparable on modality and pipeline breadth, with deeper oncology focus but adjacent autoimmune relevance.
  • Atara Biotherapeutics: Clinical-stage allogeneic T-cell therapy company with a comparable leadership connection (Kyverna CBO Dan Maziasz was formerly Atara's CBO). Atara's tabelecleucel and allogeneic platform overlap with Kyverna's KYV-201 in modality and target indications.
  • Caribou Biosciences: Clinical-stage allogeneic CAR-T developer using CRISPR-edited cell therapies (CB-010, CB-012). Comparable to Kyverna on next-generation engineered cell therapy platform though focused primarily on oncology, with potential autoimmune expansion.

Others

  • CRISPR Therapeutics: Gene-editing cell therapy company with Casgevy (exa-cel) approval and an active autoimmune pipeline (CTX112, CTX131). Thematically aligned as a next-generation cell therapy platform, with overlapping modality but differentiated gene-editing versus CAR-T approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Kyverna Therapeutics social profiles

Digital presence

Kyverna Therapeutics compliance and trust

Trust signal

Compliance3 records

Kyverna Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kyverna Therapeutics leadership team

Management profile

Number of profiles

Profiles17 records

Kyverna Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kyverna Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kyverna Therapeutics

What does Kyverna Therapeutics do?

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing CAR T-cell therapies (chimeric antigen receptor T-cell therapies) for serious B-cell-driven autoimmune diseases. Its lead candidate, mivocabtagene autoleucel (miv-cel / KYV-101), is a fully human anti-CD19 CAR T-cell therapy designed to deliver deep B-cell depletion and durable immune reset after a single infusion. The pipeline targets stiff person syndrome, generalized myasthenia gravis, multiple sclerosis, lupus nephritis, systemic sclerosis, and treatment-refractory rheumatoid arthritis.

Is Kyverna Therapeutics a public or private company?

Kyverna Therapeutics is a public company. It is classified as public and is currently ipo.

When was Kyverna Therapeutics founded?

Kyverna Therapeutics was founded in 2020. It employs 101 to 250 people.

Where is Kyverna Therapeutics based?

Kyverna Therapeutics is headquartered in Emeryville, United States, in the North America region.

How does Kyverna Therapeutics make money?

Two revenue lines are on record. Future cell therapy product sales (miv-cel / KYV-101) is the primary driver. The others are potential licensing / collaboration revenue (KYV-102 / allogeneic platform).

Who are Kyverna Therapeutics's main competitors?

Direct peers on record are Cabaletta Bio and Cartesian Therapeutics. Broad incumbents are Bristol Myers Squibb, Gilead Sciences (Kite Pharma), Novartis and Johnson & Johnson. Emerging players are Allogene Therapeutics, Atara Biotherapeutics and Caribou Biosciences. CRISPR Therapeutics is listed as an others.

Does Kyverna Therapeutics have an API?

No public API is recorded for Kyverna Therapeutics.

What industry is Kyverna Therapeutics in?

Kyverna Therapeutics's product category is Cell Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAALAK, Autoimmune & Allergy Diagnostics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
医药魔方-致力于数据赋能医药创新,助力高效决策与数智化转型Kyverna Files First Autoimmune CAR-T Therapy with US RegulatorsKyverna Therapeutics received US regulatory acceptance for its first autoimmune CAR-T therapy, mivocabtagene autoleucel, for stiff person syndrome. The Phase II study showed a 46% improvement in timed 25-foot walk at week 16 and 49% at month 12. Kyverna plans a registrational Phase III in myasthenia gravis in 2027.PR NewswireDid Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?Halper Sadeh LLC is investigating whether Kyverna Therapeutics officers and directors breached fiduciary duties to shareholders. The firm invites long-term shareholders to seek corporate governance reforms, fund returns, or other relief on a contingent fee basis.FierceBiotechKyverna abandons next-gen autoimmune CAR-T once touted as follow-up to miv-celKyverna halted development of its next-gen autoimmune CAR-T, KYV-102, and deprioritized the program. The company will focus on accelerating late-stage neurologic indications with miv-cel, which has an FDA approval application for stiff person syndrome. A potential commercial launch of miv-cel is expected in 2027.FinancialContent Business PageKyverna Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. - KYTXKahn Swick & Foti, LLC has initiated an investigation into Kyverna Therapeutics, alleging its IPO prospectus misstated or omitted material facts about the clinical evaluation of its lead product candidate KYV-101. The lawsuit claims the company concealed adverse trial data, inflating share prices and causing investor losses.MarketScreenerKyverna Therapeutics, Inc. Highlights Promising Updated Clinical Data With Miv-Cel In Progressive Multiple Sclerosis At MS Toronto 2026Kyverna Therapeutics presented updated Phase 1 data on miv-cel in progressive multiple sclerosis at MS Toronto 2026. Five of six patients showed stable or improved EDSS, with four sustaining benefit beyond one year and one beyond two years. The therapy demonstrated robust CAR T-cell expansion and deep B-cell depletion with a well-tolerated safety profile.Quiver QuantitativeKyverna Therapeutics Reports Durable Clinical Benefit and CNS Penetration With Miv-Cel in Progressive Multiple Sclerosis | KYTX Stock NewsKyverna Therapeutics reported Phase 1 trial data for miv-cel in progressive multiple sclerosis, showing durable clinical benefit and CNS penetration. The first patient sustained benefit beyond two years, and the FDA granted RMAT designation for non-active secondary progressive MS. Kyverna plans to update its development strategy by early 2027.PR NewswireDid Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?Halper Sadeh LLC is investigating whether Kyverna Therapeutics officers and directors breached fiduciary duties to shareholders. The firm invites long-term shareholders to seek corporate governance reforms, fund returns, or other relief on a contingent fee basis.Science NewsThis ‘living drug’ could change the course of autoimmune diseaseA clinical trial of CAR T cell therapy for stiff person syndrome has restored mobility for patients, including Lynn Montgomery-Haga, who can now walk without assistance. The therapy, developed by Kyverna, is seeking FDA approval and could be the first for an autoimmune condition. Researchers caution that long-term effects and safety are still unknown.BioSpaceWeighing the risks of CAR T in autoimmune disease as Kyverna nears marketKyverna Therapeutics reported one-year durability data for its CAR T therapy miv-cel in stiff person syndrome, showing improved mobility and no high-grade safety events. Novartis and BMS paused autoimmune CAR T trials after deaths and inflammatory events, but Kyverna's safety profile is attributed to its design and manufacturing process. The company plans to file a biologics license application by year-end.Les EchosUn espoir pour Céline Dion : la thérapie de la biotech Kyverna contre le syndrome de la personne raide obtient des résultats probantsKyverna announced intermediate results from its Miv-Cel therapy trial for Céline Dion's stiff-person syndrome, showing conclusive efficacy with one year of follow-up. The single-injection CAR-T cell therapy's effect amplifies over time, and its third phase is underway. It could become the first CAR-T treatment for an autoimmune disease, opening new avenues for conditions like multiple sclerosis and rheumatoid arthritis.